Prime closes $144M public offering

Prime Medicine has successfully completed its public offering of 43.7 million shares of common stock, including the full exercise of the underwriters' option for 5.7 million additional shares, raising approximately $144.2 million in gross proceeds.

The participation of the Cystic Fibrosis Foundation, which purchased approximately 1.82 million shares without underwriter discounts, represents a key vote of confidence from a respected disease foundation.

Prime and the CF Foundation inked an agreement in January 2024, investigating prime editing as a potentially curative approach for CF. Just a few weeks ago, the foundation agreed to provide Prime with up to $24 million in additional funding to accelerate the development. Prime is initially focusing on an in vivo program targeting G542X, one of the most prevalent CF-causing nonsense mutations and one for which there are no available therapies.

Back in May, Prime revealed a strategic restructuring, including the deprioritization of its chronic granulomatous disease programs, as well as a cost and 25% workforce reduction to focus on its liver franchise and programs funded through external partnerships. According to the company, the initiatives are designed to “significantly decrease Prime Medicine’s operating expenses and cash burn, reducing anticipated cash needs by almost half through 2027.”